Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE by William Stohl, Milena Kurtinecz, David A Roth, Herbert Struemper, William W Freimuth, Lisa Edwards

Get full text

Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data by Anne Hammer, Beulah Ji, David A Roth, David D'Cruz, Paige Meizlik, Gina Eriksson, Yulia Green

Get full text

Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III prog... by Ian N Bruce, Damon L Bass, David A Roth, Toni Maslen, David D'Cruz, Mihaela Ianosev, Christel Wilkinson

Get full text

Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort by Qinggong Fu, Michelle A Petri, Daniel W Goldman, David A Roth, Selin Cooper Blenkinsopp, Yulia Green, Anuradha Madan, Patricia Juliao

Get full text

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea by Damon Bass, Regina Kurrasch, Sang-Cheol Bae, Beulah Ji, David A Roth, Jenny Lowe, Myron Chu, Paula Curtis, Kathleen DeRose, Paige Meizlik

Get full text

EMBRACE: One Small Story in Lupus—One Giant Challenge in Clinical Trials by Saira Z. Sheikh, Tessa R. Englund, Susan W. Burriss, Jonca Bull, Anya Harry, James G. Groark, Ashley M. Hall, Michelle Miller, David A. Roth

Get full text

1104 Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) With Relapsed and Newly Diagnosed Active Lupus Nephritis (LN) by Brad H Rovin, Hans-Joachim Anders, Ming-hui Zhao, Ana Malvar, David A Roth, Keiju Hiromura, Jennifer Gilbride, Yulia Green, Anuradha Madan, Angela Jones- Leone, Tania Gonzalez-Rivera

Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years by Damon Bass, Regina Kurrasch, Yin Su, Jie Zheng, Yang Li, Guochun Wang, Fengchun Zhang, David A Roth, Jieruo Gu, Jenny Lowe, Myron Chu, Paula Curtis, Kathleen DeRose, Paige Meizlik, Mingjun Wang, Xingfu Li

Get full text

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison by Hermine I Brunner, Nicolino Ruperto, Clarissa A Pilkington, Damon L Bass, Mohamed Okily, Holly Quasny, Fengchun Zhang, Syuji Takei, Carlos Abud-Mendoza, Diego O Viola, Beulah N Ji, David A Roth, Masaaki Mori, Sandra Navarra, Reema Syed, Gina Eriksson, Anne E Hammer

Get full text

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome by Xavier Mariette, Francesca Barone, Chiara Baldini, Hendrika Bootsma, Kenneth L. Clark, Salvatore De Vita, David H. Gardner, Robert B. Henderson, Michael Herdman, Karoline Lerang, Prafull Mistry, Raj Punwaney, Raphaele Seror, John Stone, Paul L.A. van Daele, André van Maurik, Nicolas Wisniacki, David A. Roth, Paul Peter Tak

Get full text

Bottled water contaminant exposures and potential human effects by Paul M. Bradley, Kristin M. Romanok, Kelly L. Smalling, Michael J. Focazio, Nicola Evans, Suzanne C. Fitzpatrick, Carrie E. Givens, Stephanie E. Gordon, James L. Gray, Emily M. Green, Dale W. Griffin, Michelle L. Hladik, Leslie K. Kanagy, John T. Lisle, Keith A. Loftin, R. Blaine McCleskey, Elizabeth K. Medlock–Kakaley, Ana Navas-Acien, David A. Roth, Paul South, Christopher P. Weis

Get full text